AGC expands partnership with Novavax in U.S.

By The Science Advisory Board staff writers

August 11, 2020 -- AGC Biologics is expanding its relationship with Novavax by increasing manufacturing of Novavax's Matrix-M adjuvant for the COVID-19 vaccine candidate from its Seattle facility.

NVX-CoV2373 is Novavax's stable prefusion protein vaccine made using nanoparticle technology. AGC will optimize process development for scaled-up production of Matrix-M to enable Novavax to deliver a worldwide supply of the vaccine in 2020 and 2021.

AGC is already providing contract development and manufacturing organization services to Novavax for MatrixM from its facility in Copenhagen.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here